The in vitro effect of one traditional Chinese herbal medicine (Japanese name: "Keishibukuryo-gan"), which has been empirically used in scleroderma patients in China and Japan, on collagen production in fibroblast cultures was studied. Fibroblasts from 3 scleroderma patients and 2 normal controls were incubated with various concentrations of "Keishi-bukuryo-gan" and collagen production was then determined by a radiochemical method. "Keishi-bukuryo-gan" significantly and selectively inhibited collagen synthesis in a dose-dependent manner, with a tendency of a stronger effect on scleroderma fibroblasts than control cells. The results mayexplain the clinical usefulness of this medicine, and it may become a promising new agent for the treatment of scleroderma. (Internal Medicine 33: 466-471, 1994) 
Introduction
Scleroderma is a generalized connective tissue disorder characterized by a vascular change, an inflammatory and fibrotic change of the skin and internal organs, and various immunological abnormalities ( 1 , 2) . In particular, th^fibrosis of the lungs and heart as well as renal involvementare the major causes of morbidity and mortality in scleroderma patients. The flbrotic change is considered to result mainly from enhanced production of collagen (3) , which is associated with elevated levels of the procollagen messenger RNA(mRNA) (4) . Thus, inhibition of excessive collagen production in scleroderma cells by pharmacologic means is thought to result in reduced collagen accumulation in tissues, with subsequent clinical improvement. To date, a number of pharmacologic agents are knownto inhibit production and accumulation of collagen at various levels (5-7), and some of them such as D-penicillamine (8) , interferon-y (9), and retinoids (10) are already used for the treatment of scleroderma. However, these agents do not always provide satisfactory effects for the patients or the attending physicians. In addition and more importantly, they frequently have considerable adverse effects, and the patients maynot tolerate their long-term use. Therefore, scleroderma still remains one of the most refractory autoimmunediseases.
A traditional Chinese herbal medicine (Japanese generic name: Kampomedicine) is a natural drug extracted from one or more of various medicinal plants. Thus, Kampomedicine is generally composed of several kinds of herbal extracts, and each extract further seems to have numerous functional components which may interact with each other. Because of this complicated composition, and because each constituent has not been chemically identified in most of the Kampomedicines, scientific analyses of their beneficial effects have been difficult, and such studies have rarely been published in English literature, except for a few studies (ll).
However, the Kampo medicines are used empirically in China and also in Japan in various chronic diseases including autoimmune connective tissue disease, since theirlong-term use usually shows less toxic effects than ordinary chemical agents. There have been several reports indicating the clinical usefulness of some Kampomedicines in patients with scleroderma and mixed connective tissue disease (MCTD) in these countries (12) (13) (14) (15) (16) , although scientific endorsement of their usefulness is essentially lacking. According to these reports, the patients treated with Kampomedicines showed significant improvement in various clinical manifestations including Raynaud's phenomenon, swollen hands, sclerotic skin, and interstitial pneumonitis (12) (13) (14) (15) (16) . In the present study, we have evaluated the in vitro effect of one of the herbal medicines (Japanese name: "Keishi-bukuryogan") which has been reported to be useful for the therapy of scleroderma, on enhanced collagen synthesis by scleroderma fibroblasts. As a result, this Kampomedicine showedselective inhibition of collagen production. Along with the evidence of clinical usefulness in some scleroderma patients, the Kampo medicine may become a new promising therapeutic modality in the treatment of this intractable disease.
Materials and Methods

Patients
All of the human investigations were performed in accordance with the precepts of the Helsinki Declaration. Patients studied were 3 scleroderma patients (SSc-1 , 2, 3) who fulfilled the 1980 criteria for the classification of scleroderma ( 17) . All scleroderma patients were female, and had progressive generalized disease with proximal skin sclerosis and various internal organ involvement. Anti-topoisomerase I antibody was positive in all patients. The SSc-1 patient was 57 years old, the SSc-2 patient 43, and the SSc-3 patient 40; their disease duration was 4, 1.5, and 4 years, respectively. Skin biopsy from all patients revealed typical scleroderma changes. As a control. 2 healthy womenwere entered in the study; Control-1 was 46 years old and Control-2 32.
Fibroblast cultures Fibroblast cultures were derived from the biopsy sample of sclerotic skin of the 3 scleroderma patients, and also from the normal skin of the 2 control subjects. The cells were maintained in Dulbecco's modified Eagle's medium (DMEM)supplemented with 10% fetal calf serum (FCS) at 37°C in a humidified incubator under 5%CO2and 95%air. The cultures were studied in passages 6-1 0. Scleroderma fibroblasts and control fibroblasts were simultaneously cultured in the subsequent experiments.
Kampomedicines
All of the Kampomedicines prepared for the experiments were a spray-dried powder of hot water extracts with no conservatives and were kind donations from TsumuraJuntendo Co. Ltd., Tokyo, Japan. One gram of "Keishi-bukuryo-gan" water-soluble powder was extracted from each 1.71 g of Cinnamomi Cortex, Paeoniae Radix, Persicae Semen, Hoelen, and Moutan Cortex. "Keishi-bukuryo-gan" was dissolved in DMEM, and used in fibroblast cultures at a final concentration of 0.05% after filtration with Millex-HV 0.45 Jim filter unit (Millipore Corp., Bedford, MA, USA). In some experiments, 0.001 %, 0.005%, and 0.0 1 % concentration of"Keishi-bukuryogan" was studied. Another Kampomedicines (Japanese name: "Hachimi-jio-gan" and "Keishi-ka-jutsubu-to")
were also used at a final concentration of 0.05% in some experiments.
Collagen assays
The assays were performed according to those reported previously (7, 1 8) . Briefly, after 4xlO4 cells/well were plated in 24-well tissue culture plates and incubated for 2 days, the cultures were rinsed, and 1 ml of DMEM supplemented with 1% dialyzed FCS, 50 |ig/ml of ascorbic acid, and 25 |lg/ml of B-aminopropionitrile with or without the Kampomedicine tested was added to the cultures. After appropriate incubation time (mostly 12 hours), 370 kBq (10 jiCi) of L-[2,3,4,5-3H]-proline (specific activity 103 Ci/mmole; Amersham International, Buckinghamshire, UK) was added, and the incubations were continued for 6 hours. At the end of incubation, the mediumwasremoved,and the solution ofproteinase inhibitors containing N-ethyl-maleimide , phenylmethylsulfonyl fluoride , and ethylenediamine tetraacetic acid was added. The cells on the plate were sonicated in Tris-buffer containing proteinase inhibitors. Aliquots of the media and cell homogenates were dialyzed, and then hydrolyzed with 12 N HC1 for 18 hours at 1 20°C. Finally, the 3H-hydroxyproline content was determined by radiochemical methods and the synthesis of radioactive hydroxyproline in the non-dialyzed fraction was taken as an index of collagen production. Determinations were done usually in triplicates. Aliquots of the cell homogenates were also used for protein determination in a dye binding assay (19) .
Non-collagenous protein assays
The fibroblast cultures were prepared as described in the methods for collagen assays, but the cultures were labeled with 1 85 kBq (5 jiCi) ofL-[5-3H] -tryptophan (specific activity 25 Ci/ mmole; Amersham International).
At the end of incubation, proteinase inhibitors as described above were added to the medium. Non-collagenous protein synthesis was determined by precipitation of the mixture of culture supernatants and sonicated cell homogenates with an equal volume of cold 20% trichloroacetic acid (TCA). The precipitates were collected on glass-fiber filters using a vacuumfiltration manifold, washed twice with 10% TCA, air-dried, and then counted by a liquid scintillation counter.
Fibroblast proliferation assays
To determine the effect of the Kampomedicine on fibroblast proliferation, 4xlO3 cells/well were plated in a 96-well tissue culture plate, and preincubated for 12 hours in DMEM supplemented with 1 % FCS with or without 0.05% "Keishi-bukuryogan". After labeled with 74 kBq (2 jllQ) of [methyl-3H]-thymidine (specific activity 80 Ci/mmole; Amersham International) for 6 hours, the cells were detached from the wells by brief trypsinization, and the 3H-thymidine-containing macromolecules were collected on glass-fiber filters using a cell harvester (PHD, Cambridge Medical Technology Inc. , Billerica, MA,USA). The radioactivity on the filters was determined by a liquid scintillation counter.
In addition, the effect of the Kampomedicine on the fibroblast viability was determined by trypan blue dye exclusion test.
Effect of serum of persons whotook the Kampomedicine To examine whether there was an inhibitory effect in the serum of the persons who took the Kampomedicine, an ordinary dose (7.5 g/day) of "Keishi-bukuryo-gan" which was equivalent to 1.75 g of extract powder used for the in vitro experiment was administered to 3 healthy individuals, 22-and 24-year-old men and a 32-year-old woman, for 4 weeks, after having obtained their consent. Peripheral blood was obtained before and 1 and 4 weeks after starting administration of the Internal Medicine Vol. 33, No. 8 (August 1994) drug. Blood aspiration was done 2-3 hours after the last administration. Each serum was dialyzed against DMEM and heat-inactivated after filtration. DMEM containing 20% of each serum was added to the cultured scleroderma fibroblasts and collagen production was assayed as described above.
Statistical analysis
The statistical significance of the differences was analyzed using Student' s t-test.
Results
In the preliminary experiments, various periods of incubation with the Kampo medicineand various concentrations were tested. As shown in Fig. 1 , preincubation with "Keishi-bukuryogan" for 12 hours before adding radio-labeled proline showed a maximuminhibitory effect on collagen production by fibroblasts treated with the drug, without an apparent effect on collagen production by untreated fibroblasts. Preincubation for 24 hours caused inhibition also in untreated cells, probably due to a low concentration of FCS. Therefore, preincubation with the drug was performed for 12 hours in further experiments. Figure 2 showed a dose-dependent inhibitory effect of "Keishibukuryo-gan" on collagen production in the SSc-1 and Control-1 cell cultures. At all of the concentrations tested, a greater inhibitory effect was seen in the SSc-1 than the Control-1 cells; at 0.005% concentration of "Keishi-bukuryo-gan" SSc-1 cells showed 40.6% inhibition (p<0.05 vs. untreated condition) and Control-1 cells showed 27. 1 % inhibition (p<0.05 vs. untreated condition); at 0.01% concentration SSc-1 cells showed 47.8% inhibition and Control-1 cells showed 4 1.9% inhibition; and at 0.05% concentration SSc-1 cells showed 86.0% inhibition and Control-1 cells showed 78.5% inhibition. In most of the further experiments, 0.05% concentration of the drug was used. Figure 3 showed collagen production by 3 fibroblast lines from the scleroderma patients and 2 fibroblast lines from the controls. Whencompared as a group, scleroderma fibroblast group spontaneously produced more collagen than the control group (p<0.01) as reported previously (3, 4, 7) , although the amount varied amongindividuals. In the presence of 0.05% "Keishi-bukuryo-gan" in the medium, collagen production was significantly inhibited in all of the fibroblast lines (p<0.05). The rate of inhibition was 87.8% in SSc-1 cells, 71.5% in SSc-2, 76.9% in SSc-3, 75.0% in Control-1 and 54.8% in Control-2, thus indicating a tendency toward greater inhibition of collagen production by "Keishi-bukuryo-gan" in scleroderma cells than in control cells. Wealso studied the effect of "Keishi-bukuryo-gan" on the production of non-collagenous proteins by analyzing 3H-tryptophan incorporation. As a result, this drug did not affect thê Effect of "Keishi-bukuryo-gan" on collagen production in scleroderma fibroblast cultures for various incubation times. Scleroderma fibroblasts (SSc-3) were cultured in Dulbecco's modified Eagle's medium containing 1 %fetal calf serum with or without 0.05% "Keishi-bukuryo-gan" for various times (1-24 hours) and labeled with 3H-proline for an additional 6 hours, and then radioactive hydroxyproline was assayed as an index of newly synthesized collagen (see Materials and Methods). Values are the mean±SDof triplicates. At each preincubation time, "Keishi-bukuryo-gan" significantly (p<0.05) inhibited collagen production, but the specific inhibition by the drug was the greatest with preincubation for 12 hours. production of non-collagenous proteins in both SSc-1 cells and
Control-1 cells (data not shown), suggesting that "Keishibukuryo-gan" selectively inhibited collagen synthesis.
Then, the drug was tested for its influence on the proliferation of fibroblasts by analyzing the incorporation of3H-thymidine into the cells. Figure 4 shows an almost equal level ofprolifera- 
Three healthy volunteers took 7.5 g/day of "Keishi-bukuryo-gan" for 4 weeks and serum from each volunteer was obtained before taking this drug and 1 and 4 weeks after beginning the administration of the drug. Scleroderma flbroblasts (SSc-1) were cultured in the medium containing 20% of each serum and collagen production was assayed (see Materials and Methods). Values are the mean±SD. In each volunteer, no significant difference in collagen production was demonstrated before and after administration of the drug.
tion between the SSc-1 and Control-1 fibroblasts in the absence of the drug, and also that "Keishi-bukuryo-gan" inhibited the proliferation of scleroderma and control cells similarly in a concentration-dependent manner. However, the trypan blue dye exclusion test revealed that the viability of both cells was not affected by incubation with 0.05% concentration of this drug for 12 hours (data not shown).
In further experiments, an additional 2 drugs which have also been clinically used in scleroderma patients (12, 13, 15) were examinedfor their effect on collagen synthesis (data not shown). Both "Hachimi-jio-gan" and "Keishi-ka-jutsubu-to" significantly inhibited the collagen synthesis in both SSc-1 and Control-1 fibroblast cultures (p<0.05 vs. untreated condition). However, these 2 drugs had less inhibitory effect as compared with "Keishi-bukuryo-gan" (p<0.05).
To make a rough estimate of the in vivo effect of "Keishibukuryo-gan", sera from 3 healthy volunteers who had taken this medicine for 4 weeks were tested for its influence on the synthesis of collagen in fibroblast cultures. No definite inhibition ofcollagen production wasobserved whensera obtained 1 and 4 weeks after beginning the administration of the drug was added in 20% concentration to the culture medium (Table 1) . However, 2 of 3 subject's sera obtained after drug administration showed a little inhibitory effect on collagen synthesis in vitro.
Discussion
The present study demonstrated that "Keishi-bukuryo-gan" significantly and selectively inhibited collagen synthesis in vitro, with a tendency of a stronger effect on scleroderma fibroblasts than on control cells. In addition, this drug showed an inhibition on fibroblast proliferation without affecting cell hysteromyoma. Because of its known action of promoting blood circulation and removing peripheral blood stasis, the clinical application of "Keishi-bukuryo-gan" was gradually extended, and recently in China and Japan it has been used also in some rheumatic diseases including scleroderma (12) (13) (14) , MCTD(16), Behcet's disease (20), and Sjogren's syndrome (21). In addition to the beneficial effect on peripheral blood circulation, the present results showing an inhibitory effect on collagen production suggest the positive application of"Keishibukuryo-gan" for the therapy of not only Raynaud's phenomenon but also sclerosis of the skin and internal organs, and thus mayaccount for the clinical usefulness of this medicine which has been empirically used in patients with scleroderma. Because of its nature as a mixed composition of numerous unknownfunctioning components, it seems impossible to identify which component(s) of the Kampomedicine contributes to the inhibitory effect on collagen synthesis observed in the present study. In three types of Kampomedicine showing an inhibition of collagen production, the only commonextract was that from Cinnamomi Cortex. However, the amount of CinnamomiCortex extract varied in these three drugs and the amount was not parallel with the inhibitory effect, suggesting that the inhibition could not be explained by the action of this extract alone. Generally, the beneficial effect of the Kampo medicine is believed to result from an integrated action of the compounds. For identification of the extract(s) or the constituent(s) mainly responsible for the inhibitory effect, it maybe necessary to study the effect of each single extract or possible single componentwhich constitutes the drug.
It is also very difficult to determine the concentration of the Kampomedicine in the serum or tissue of an individual taking the medicine because of the nature of the drug. Therefore, it is unclear whether the 0.005%-0.05% concentration of "Keishibukuryo-gan" that showed an inhibition of collagen synthesis in fibroblast cultures can actually be attained within some tissues with the administration of the ordinary dose. To makean approximate estimation of in vivo efficacy of "Keishi-bukuryogan", we studied the effect of sera obtained from 3 individuals who had been taking the ordinary dose of this drug for 4 weeks. There was only a tendency of an inhibitory effect on collagen production in the sera from 2 of the individuals, but we could not obtain a significant result in the present experiment. This may be partly due to the small number of volunteers studied and the short-term administration. Future experiments using a sufficient number of volunteers with prolonged administration of the drug may reveal more apparent inhibitory effect as seen in the present in vitro study. In general, the Kampomedicine is known to have a mildly beneficial effect and less toxic side effects compared with ordinary chemical agents, and therefore is more suitable for long-term use. Scleroderma is a chronic disease and in many cases the drugs are used for years. Webelieve Kampomedicines such as "Keishi-bukuryo-gan" can be recommended for patients with scleroderma, especially for those with less progressive or limited scleroderma, whereas for patients with rapidly progressive disease more aggressive agents such as Dpenicillamine, cytotoxic agents, and interferon-y may well be used.
In the preliminary experiment, there was no significant difference in a! (I) procollagen mRNAlevels between untreated and "Keishi-bukuryo-gan"-treated flbroblasts, suggesting that the inhibition of collagen synthesis might occur at a posttranscriptional level (Ohta A, et al, unpublished observation). Despite limited information about the mechanismof inhibition and also despite the lack of information about the precise nature of the active component(s), the present results suggest that someKampomedicines maybecomea new promising agent in the treatment of scleroderma.
